Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

661 Neuwelt CM, Francisco S, Lacks S, Kaye BR, Ellman JB, David GB. Role of intravenous
cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus
erythematosus. Am J Med 1995; 98: 32–41.
662 Bodani M, Kopelman M. A psychiatric perspective on the therapy of psychosis in systemic
lupus erythematosus. Lupus 2003; 12: 947–949.
663 Fong KY, Thumboo J. Neuropsychiatric lupus: clinical challenges , brain-reactive
autoantibodies and treatment strategies. Lupus 2010; 19: 1399–1403.
664 Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus
erythematosus: a systematic review. Scand J Rheumatol 2007; 36: 329–337.
665 Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide
followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115: 59–62.
666 Narváez J, Ríos-Rodriguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero
C et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence.
Semin Arthritis Rheum 2011; 41: 364–372.
667 Prevoo M, van´t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P. Modified
disease activity scores thar included twenty-eight-joint counts. Development and
validation in a prospective longitudinal study of patients with rheumatic arthritis. Arthritis
Rheum 1995; 38: 44–48.
668 Bang S-Y, Lee CK, Kang YM, Kim H-A, Suh C-H, Chung WT et al. Multicenter
retrospective analysis of the effectiveness and safety of rituximab in korean patients with
refractory systemic lupus erythematosus. Autoimmune Dis 2012; 2012: 1–6.
669 Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity
and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus
erythematosus. Arthritis Rheum 2006; 54: 2983–2988.
670 Islam N, Hossain M, Haq SA, Alam MN, Klooster PMTEN, Rasker JJ. Efficacy and safety
of methotrexate in articular and cutaneous manifestations of systemic lupus
erythematosus. Int J Rheum Dis 2012; 15: 62–68.
671 Moosig FÃ, Zeuner R, Renk C, Schro JO. IL-1RA in refractory systemic lupus
erythematosus. Lupus 2004; 13: 605–606.
672 Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results
of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with
severe lupus arthritis. Ann Rheum Dis 2005; 64: 630–633.
673 Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley M-A. Nonrenal disease
activity following mycophenolate mofetil or intravenous cyclophosphamide as induction
treatment for lupus nephritis: findings in a multicenter, prospective, randomized, openlabel,
parallel-group clinical trial. Arthritis Rheum 2010; 62: 211–221.
674 Albrecht J, Taylor ÃL, Berlin JA, Dulay S, Ang ÃG, Fakharzadeh S et al. The CLASI
(Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome
Instrument for Cutaneous Lupus Erythematosus. J Invest Dermatol 2005; 125: 889–894.
GUÍA DE PRÁCTICA CLÍNICA SOBRE LUPUS ERITEMATOSO SISTÉMICO 485